UPDATE 10 SEP 2021.
3 years ago, I wrote about an emerging type of peptide receptor radionuclide therapy (PRRT) suggesting it could be next generation. That work continues. It was being labelled with the term “Targeted Alpha-emitter Therapy (TAT)” using “alpha particles”. The current approved types of PRRT use beta particles so is a totally different method. You might be thinking what the differences are and how does it affect me? You can read more in my article PRRT – The Sequel? – Targeted Alpha-emitter Therapy (TAT).
I also wrote about the term THERANOSTICS, a combo term for THERAPY and DIAGNOSTICS. In the same way that you have a theranostic pair in Ga68 PET and Lu177 DOTATATE/DOTATOC, alpha particle therapy will need the same approach in order that specialists know the output from the diagnostic imaging, will have a therapeutic effect using alpha therapy.
So, it is good to see trials emerging along these lines. VMT-𝛼-NET is entering a Phase 1 imaging study followed by a Phase 1 therapy study for neuroendocrine tumours at the University of Iowa.
VMT = Viewpoint Molecular Targeting
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 (i.e. 212Pb mentioned in the TAT article above) to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. The type of imaging agent is not known but it’s possible they will use existing one such as Ga68 Dotatate/toc/noc or Cu64 Dotatate. This ‘theranostic’ approach enables the ability to see the specific tumour and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
VMT-𝛼-NET is designed to deliver powerful alpha particle radiation specifically to the NET, while minimizing risk to normal organs and tissues. In 2019, the University of Iowa was awarded an R01 research grant from the National Cancer Institute (NCI) to prepare for and conduct an image-guided alpha-particle therapy trial of VMT-𝛼-NET for NETs. The first-in-human imaging trial is anticipated to commence in early 2021. Viewpoint has further been awarded over $4M in the form of Small Business Innovation Research grants from the NCI to advance this cutting edge treatment to clinical development. Thus, the VMT-𝛼-NET receptor-targeted alpha-particle radiotherapy is positioned to advance a new transformative treatment paradigm for NET patients.
The Phase 1 imaging study will evaluate [203Pb]VMT-𝛼-NET as an agent for imaging somatostatin receptor subtype 2 (SSTR2)-positive neuroendocrine tumors. The images obtained will inform future therapeutic trials of [212Pb]VMT-𝛼-NET alpha-particle therapy for this tumor type. In parallel to this investigator initiated imaging trial, the Company plans to move forward with a Phase 1/2a therapy study of VMT-𝛼-NET for the treatment of neuroendocrine tumors. Details of this clinical trial can be found here.
The Company’s melanoma (VMT01) and neuroendocrine tumour (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumours at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website viewpointmt.com.
Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.
Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Subscribe to my newsletter
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here